Share chart Zenith Capital Corp.
Extended chart
Simple chart
About Zenith Capital Corp.
Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. Its lead compound ZEN-3694 which is in Phase 2b clinical trials for the treatment of metastatic castration resistant prostate cancer and metastatic triple negative breast cancer. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. The company was incorporated in 2013 and is headquartered in Calgary, Canada.| Industry | Biotechnology |
|---|---|
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.zenithepigenetics.com |
| Цена ао | 0.0001 |
| Change price per day: | 0% (0.0001) |
|---|---|
| Change price per week: | -99.8% (0.05) |
| Change price per month: | 0% (0.0001) |
| Change price per 3 month: | 0% (0.0001) |
| Change price per half year: | -99.88% (0.08) |
| Change price per year: | -99.94% (0.18) |
| Change price per 3 year: | -99.94% (0.156) |
| Change price per year to date: | -99.9% (0.1) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Donald J. McCaffrey | Chairman, President & CEO | 99.12k | |
| Mr. Aaron Bradley Cann C.A., CPA, CBV | CFO & Secretary | 42.54k | |
| Dr. Sanjay Lakhotia M.B.A., Ph.D. | Chief Business Officer | 317.15k | |
| Dr. Henrik Claus Hansen Ph.D. | Senior Vice President of Operations | 234.23k |
Address: Canada, Calgary. AB TE L, 4820 Richard Road SW - open in Google maps, open in Yandex maps
Website: https://www.zenithepigenetics.com
Website: https://www.zenithepigenetics.com
